recent publications

• academic article

  • Aronow, H. D., Califf, R. M., Harrington, R. A., Vallee, M., Graffagnino, C., Shuaib, A., Fitzgerald, D. J., Easton, J. D., Van de Werf, F., Diener, H. C., Ferguson, J., Koudstaal, P. J., et al. Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the bravo trial) American Journal of Cardiology  2008 102:1285-1290  DOI:10.1016/j.amjcard.2008.07.019  PMID:18993142
  • Topol, E. J., Easton, D., Harrington, R. A., Amarenco, P., Califf, R. M., Graffagnino, C., Davis, S., Diener, H. C., Ferguson, J., Fitzgerald, D., Granett, J., Shuaib, A., et al. Randomized, double-blind, placebo-controlled, international trial of the oral iib/iiia antagonist lotrafiban in coronary and cerebrovascular disease Circulation  2003 108:399-406  DOI:10.1161/01.cir.0000084501.48570.f6  PMID:12874182
  • Topol, E. J., Easton, J. D., Amarenco, P., Califf, R., Harrington, R., Graffagnino, C., Davis, S., Diener, H. C., Ferguson, J., Fitzgerald, D., Shuaib, A., Koudstaal, P. J., et al. Design of the blockade of the glycoprotein iib/iiia receptor to avoid vascular occlusion (bravo) trial American Heart Journal  2000 139:927-933  DOI:10.1067/mhj.2000.105107  PMID:10827369